ReviewGeroScience2017
Cytomegalovirus (CMV) research in immune senescence comes of age: overview of the 6th International Workshop on CMV and Immunosenescence.
Review in GeroScience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 56 citations in OpenAlex.
- Oxidative stress, inflammation, and apoptosis in Alzheimer's disease associated with HSV-1 and CMV coinfection.Virology journal · 2025Trial
- Subclinical Reactivation of Cytomegalovirus Drives CD4+CD28null T-Cell Expansion and Impaired Immune Response to Pneumococcal Vaccination in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.The Journal of infectious diseases · 2019Trial
- Seroprevalence of human cytomegalovirus in blood donors.GMS hygiene and infection control · 2026Article
- The mRNA-1647 vaccine: A promising step toward the prevention of cytomegalovirus infection (CMV).Human vaccines & immunotherapeutics · 2025Review
- Human cytomegalovirus infection-induced lymphocytosis diagnosed by metagenomic next-generation sequencing: a case report and literature review.Frontiers in immunology · 2025Review
- Characterisation of specific responses to three models of viral antigens in immunocompetent older adults.Immunity & ageing : I & A · 2024Article
- Article
- Cytomegalovirus Diseases of the Gastrointestinal Tract in Immunocompetent Patients: A Narrative Review.Viruses · 2024Review
- Activation of senescence in critically ill patients: mechanisms, consequences and therapeutic opportunities.Annals of intensive care · 2024Review
- Sicilian semi- and supercentenarians: identification of age-related T-cell immunophenotype to define longevity trait.Clinical and experimental immunology · 2023Article
- Premature T cell aging in major depression: A double hit by the state of disease and cytomegalovirus infection.Brain, behavior, & immunity - health · 2023Article
- T cell senescence and impaired CMV-specific response are associated with infection risk in kidney transplant recipients.Human immunology · 2022Article
- Investigating population-level immunosenescence: From bench to bedside.Frontiers in immunology · 2022Review
- Cross Talk between Inflammation and Metabolic Disorders.Mediators of inflammation · 2022Article
- Understanding the interaction between cytomegalovirus and tuberculosis in children: The way forward.PLoS pathogens · 2021Review
- Natural Products and Their Derivatives against Human Herpesvirus Infection.Molecules (Basel, Switzerland) · 2021Review
- Predictive factors of human cytomegalovirus reactivation in newly diagnosed glioblastoma patients treated with chemoradiotherapy.Journal of neurovirology · 2021Observational
- Cytomegalovirus Infection and Its Relationship with Leukocyte Telomere Length: A Cross-Sectional Study.Mediators of inflammation · 2021Article
- Advances in cytomegalovirus (CMV) biology and its relationship to health, diseases, and aging.GeroScience · 2020Review
- Human Cytomegalovirus Infection in Women With Preexisting Immunity: Sources of Infection and Mechanisms of Infection in the Presence of Antiviral Immunity.The Journal of infectious diseases · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Cytomegalovirus (CMV) is one of the most complex and most ubiquitous latent persistent viruses, with a considerable ability to evade and manipulate the immune system. Following an early-life infection, most immunocompetent humans spend several decades living with CMV, and, because the virus in these hosts does not cause manifest disease, CMV can be considered part of normal aging for more than half of humanity. However, there is accumulating evidence that CMV carriage is not a null event and that both potentially harmful and potentially beneficial outcomes emanate from the interaction of CMV with its mammalian hosts. This article provides an overview of the 6th International Workshop on CMV and Immunosenescence, highlighting the advances in the field made in the past two years, as related to CMV epidemiology/geroscience, CMV virology with an accent on latency, and CMV immune evasion and immune recognition of the virus and its antigens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.